Article
Pharmacology & Pharmacy
Long He, Shuting Wen, Zhuotai Zhong, Senhui Weng, Qilong Jiang, Hong Mi, Fengbin Liu
Summary: The combination of 5-ASA and SAHA showed lower toxicity and alleviated inflammation more effectively in the treatment of UC. One possible mechanism of synergy is the synergistic inhibition of the NF-kB signaling pathway.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Hossein Shahdadi Sardou, Fatemeh Sadeghi, Hadi Afrasiabi Garekani, Abbas Akhgari, Amir Hossein Jafarian, Mohammadreza Abbaspour, Ali Nokhodchi
Summary: The aim of this study was to evaluate and optimize the combination of time and pH-dependent polymers as a single coating for the design of the colon-specific drug delivery system of 5-aminosalicylic acid (5-ASA) pellets. The ratio of ES:EL:EC of 33:52:15 w/w at a coating level of 7% was discovered as the optimum coating for the delivery of 5-ASA matrix pellets to the colon.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2023)
Article
Gastroenterology & Hepatology
Ohad Atia, Ramit Magen Rimon, Natan Ledderman, Shira Greenfeld, Revital Kariv, Yiska Loewenberg Weisband, Ron Shaoul, Eran Matz, Shmuel Odes, Idan Goren, Henit Yanai, Iris Dotan, Dan Turner
Summary: A nationwide study in Israel showed that 18% of patients with UC do not receive maintenance treatment, and half of them remain untreated after 3 years. The outcomes of untreated patients were similar to those of treated patients. Further research is needed to explore the role of NMT in UC.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Arshdeep Singh, Vandana Midha, Kirandeep Kaur, Ramit Mahajan, Dharmatma Singh, Ramandeep Kaur, Aditya Kohli, Avantika Chawla, Kriti Sood, Namita Bansal, Ajit Sood
Summary: There is no difference in the efficacy and safety of tofacitinib and oral prednisolone for induction of remission at 8 weeks in patients with moderately active UC.
JOURNAL OF CROHNS & COLITIS
(2023)
Review
Biochemistry & Molecular Biology
Emanuele Sinagra, Francesco Vito Mandarino, Marcello Maida, Daniela Cabibi, Francesca Rossi, Dario Raimondo, Guido Manfredi
Summary: Focal active colitis (FAC) refers to the isolated finding of neutrophil infiltration in the colonic crypts, causing debates about its clinical significance. This narrative review aims to provide an overview of the available evidence regarding the clinical implications of FAC in both adults and pediatric populations.
Article
Pharmacology & Pharmacy
Peishan Qiu, Lan Liu, Jun Fang, Meng Zhang, Haizhou Wang, Yanan Peng, Min Chen, Jing Liu, Fan Wang, Qiu Zhao
Summary: This study identified CASP1, SERPINA1, and CCL2 as hub genes related to autophagy in active UC. Moreover, SERPINA1 may serve as a new pharmacological autophagy regulator of UC, providing a new target for small molecules targeting autophagy in the treatment of active UC.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Gastroenterology & Hepatology
Sonya S. Dasharathy, Millie D. Long, Jeffrey M. Lackner, Dana Ben-Ami Shor, Liu Yang, Nir Bar, Christina Ha, Guy A. Weiss
Summary: Poor adherence to oral medications in patients with ulcerative colitis (UC) was associated with lower perceived competence and worse relationship with healthcare providers.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Abhishek Bhurwal, Carlos D. Minacapelli, Anish Patel, Hemant Mutneja, Akshay Goel, Ishani Shah, Vikas Bansal, Bhaumik Brahmbhatt, Kiron M. Das
Summary: This study revealed racial and geographical disparities in colectomy rates among hospitalized patients with UC after the introduction of anti-TNF therapy. African American and Hispanic patients had significantly lower colectomy rates compared to White patients, while the western regions of the United States had the highest colectomy rates. Further research is needed to understand the underlying social and biological factors contributing to these disparities.
INFLAMMATORY BOWEL DISEASES
(2022)
Review
Gastroenterology & Hepatology
Brigida Barberio, Jonathan P. Segal, M. Nabil Quraishi, Christopher J. Black, Edoardo Savarino, Alexander C. Ford
Summary: Topical mesalazine and combined oral and topical mesalazine are the most effective in inducing remission for ulcerative colitis. High-dose oral mesalazine has more evidence for inducing remission and is significantly more effective than lower doses.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Biochemistry & Molecular Biology
Raaj S. Mehta, Jared R. Mayers, Yancong Zhang, Amrisha Bhosle, Nathaniel R. Glasser, Long H. Nguyen, Wenjie Ma, Sena Bae, Tobyn Branck, Kijun Song, Luke Sebastian, Julian Avila Pacheco, Hyuk-Soo Seo, Clary Clish, Sirano Dhe-Paganon, Ashwin N. Ananthakrishnan, Eric A. Franzosa, Emily P. Balskus, Andrew T. Chan, Curtis Huttenhower
Summary: A multi-omics workflow was used to identify the microbial pathways responsible for the degradation of the drug 5-ASA in patients with inflammatory bowel disease. The study found 12 previously uncharacterized microbial acetyltransferases associated with 5-ASA inactivation. In addition, three microbial thiolases and one acyl-CoA N-acyltransferase were found to be epidemiologically associated with an increased risk of treatment failure among 5-ASA users.
Article
Gastroenterology & Hepatology
Chikako Watanabe, Masakazu Nagahori, Toshimitsu Fujii, Kaoru Yokoyama, Naoki Yoshimura, Taku Kobayashi, Hirokazu Yamagami, Kazuya Kitamura, Kagaya Takashi, Shiro Nakamura, Makoto Naganuma, Shunji Ishihara, Motohiro Esaki, Maria Yonezawa, Reiko Kunisaki, Atsushi Sakuraba, Naoaki Kuji, Soichiro Miura, Toshifumi Hibi, Yasuo Suzuki, Ryota Hokari
Summary: This study found that non-adherence to mesalamine was underestimated by physicians in pregnant UC patients, leading to disease relapse and potentially adverse pregnancy outcomes. Non-adherence was identified as an independent risk factor for relapse and could impact pregnancy outcomes. Preconceptional education on medication safety and avoiding self-discontinuation is necessary for these patients.
DIGESTIVE DISEASES AND SCIENCES
(2021)
Article
Engineering, Environmental
Li Zhao, Fei Wang, Zhengwei Cai, Qi Zhou, Bo Chen, Chen Zhang, Hua Liu, Liwen Hong, Tianyu Zhang, Jie Zhong, Wenguo Cui, Zhengting Wang
Summary: The use of G4 PAMAM dendrimer to construct G4-ASA nanoparticles significantly increased the solubility of 5-ASA, resulting in the development of an injectable adhesive 5-ASA-loaded hydrogel. This new formulation demonstrated superior efficacy in alleviating symptoms of ulcerative colitis in experimental models.
CHEMICAL ENGINEERING JOURNAL
(2021)
Article
Gastroenterology & Hepatology
David T. Rubin, Iris Dotan, Aaron DuVall, Yoram Bouhnik, Graham Radford-Smith, Peter D. R. Higgins, Daniel S. Mishkin, Pablo Arrisi, Astrid Scalori, Young S. Oh, Swati Tole, Akiko Chai, Kirsten Chamberlain-James, Stuart Lacey, Jacqueline McBride, Julian Panes
Summary: Etrolizumab showed superiority over placebo in inducing remission in HIBISCUS I, but not in HIBISCUS II. Etrolizumab was well tolerated in both studies.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Edward V. Loftus, Severine Vermeire, Brian G. Feagan, Franck-Olivier Le Brun, Alessandra Oortwijn, Ulrik Moerch, William J. Sandborn, Toshifumi Hibi
Summary: In patients with ulcerative colitis, the study found that 200 mg of filgotinib can reduce the use of corticosteroids and maintain corticosteroid-free clinical remission. Moreover, compared to other medications, filgotinib demonstrated better outcomes in patients who had not previously used biologic agents.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Chemistry, Multidisciplinary
Chao Deng, Yiwei Hu, Mariana Conceicao, Matthew J. A. Wood, Hongyao Zhong, Yan Wang, Ping Shao, Jinghua Chen, Lipeng Qiu
Summary: A LbL-Exos self-assembly system was constructed for the oral delivery of exosomes targeted to the colon. The system protected the exosomes from degradation and effectively alleviated ulcerative colitis through anti-inflammatory and tissue repair effects. Additionally, it improved UC via MAPK/NF-kappa B signaling pathway inhibition.
JOURNAL OF CONTROLLED RELEASE
(2023)
Article
Oncology
Debasish Tripathy, Joanne L. Blum, Gabrielle B. Rocque, Aditya Bardia, Meghan S. Karuturi, Joseph C. Cappelleri, Yuan Liu, Zhe Zhang, Keith L. Davis, Yao Wang
Article
Health Care Sciences & Services
Ravi K. Goyal, Gebra Cuyun Carter, Saurabh P. Nagar, Emily Nash Smyth, Gregory L. Price, Rohan C. Parikh, Yu-Jing Huang, Li Li, Keith L. Davis, James A. Kaye
Summary: The study found an increasing use of chemotherapy as patients progressed, while the utilization of endocrine therapy in the first-line treatment decreased. A total of 278 unique treatment regimens were used in the first-line setting, highlighting the economic burden of HR+/HER2- metastatic breast cancer patients.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
(2021)
Article
Oncology
Amit G. Singal, Saurabh P. Nagar, Abby Hitchens, Keith L. Davis, Shrividya Iyer
Summary: This study confirmed the clinical effectiveness of first-line lenvatinib monotherapy for unresectable hepatocellular carcinoma, providing evidence for its efficacy in real-world settings.
Article
Oncology
Ravi K. Goyal, Preetesh Jain, Saurabh P. Nagar, Hannah Le, Shaum M. Kabadi, Keith Davis, James A. Kaye, Xianglin L. Du, Michael Wang
Summary: This population-based study of mantle cell lymphoma patients in the United States Medicare system found that BR was the preferred first-line treatment with higher overall survival compared to other regimens, with ibrutinib having lower survival rates. Patients with more adverse events experienced significantly higher monthly costs, indicating a greater economic burden.
LEUKEMIA & LYMPHOMA
(2021)
Article
Oncology
Ravi K. Goyal, Saurabh P. Nagar, Shaum M. Kabadi, Hannah Le, Keith L. Davis, James A. Kaye
Summary: Background information on overall survival and adverse events in patients with chronic lymphocytic leukemia (CLL) is mostly available from clinical trials. We conducted a population-based retrospective cohort study to assess OS, incidence of AEs, and economic burden in real-world practice among Medicare patients treated for CLL. Over two-thirds of patients survived at least 2 years after starting their first observed therapy for CLL. Our findings highlight considerable susceptibility to AEs and unmet medical need in Medicare patients with CLL treated in routine practice.
Review
Pharmacology & Pharmacy
Riyaz Shah, Nicolas Girard, Saurabh P. Nagar, Frank Griesinger, Julia Roeper, Keith L. Davis, Parisa Karimi, William Sawyer, Ning Yu, Aliki Taylor, Josephine Feliciano
Summary: The study found that approximately 73% of patients with EGFR mutation-positive advanced/metastatic non-small cell lung cancer in Europe and the USA experience disease progression after receiving first- or second-generation EGFR-TKI treatment. Despite 74% of patients undergoing T790M testing, only half tested positive, with most of them receiving osimertinib treatment.
DRUGS-REAL WORLD OUTCOMES
(2021)
Editorial Material
Gastroenterology & Hepatology
Amit G. Singal, Saurabh P. Nagar, Abby Hitchens, Keith L. Davis, Shrividya Iyer
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Pharmacology & Pharmacy
Juliana Meyers, Meredith Hoog, Reema Mody, Maria Yu, Keith Davis
Summary: The study evaluated healthcare costs and cardiovascular outcomes among US patients with type 2 diabetes and cardiovascular disease or risk factors. Findings showed that costs were substantial for these patients, with a proportion of CV risk patients being diagnosed with emergent CVD during follow-up.
CLINICAL THERAPEUTICS
(2021)
Article
Medicine, General & Internal
Reema Mody, Juliana Meyers, Maria Yu, Keith Davis, Joshua A. Levine
Summary: This study reports on the use of antihyperglycemic agents (AHAs) in patients with type 2 diabetes (T2D) and cardiovascular disease (CVD) or cardiovascular risk (CV risk) factors in the United States. The use of GLP-1 RAs and SGLT2 inhibitors increased during the study period, but most patients, particularly those aged 65 years and above, did not receive these medications.
CURRENT MEDICAL RESEARCH AND OPINION
(2022)
Article
Hematology
Gilles Salles, Stephen J. Schuster, Martin Dreyling, Luca Fischer, John Kuruvilla, Piers E. M. Patten, Bastian von Tresckow, Sonali M. Smith, Ana Jimenez-Ubieto, Keith L. Davis, Carla Anjos, Jufen Chu, Jie Zhang, Chiara Lobetti Bodoni, Catherine Thieblemont, Nathan H. Fowler, Michael Dickinson, Joaquin Martinez-Lopez, Yucai Wang, Brian K. Link
Summary: The ELARA trial demonstrates that tisagenlecleucel (tisa-cel) is highly effective in treating relapsed or refractory follicular lymphoma (r/r FL). Compared to usual care, tisa-cel showed significantly higher complete response rate, overall response rate, and improved survival outcomes at 12 months.
Review
Oncology
Juergen Wolf, Pierre-Jean Souquet, Koichi Goto, Alexis Cortot, Christina Baik, Rebecca Heist, Tae Min Kim, Ji-Youn Han, Joel W. Neal, Aaron S. Mansfield, Isabelle Gilloteau, Ngozi Nwana, Maeve Waldron-Lynch, Keith L. Davis, Monica Giovannini, Mark M. Awad
Summary: MET inhibitor therapy has shown better survival outcomes in patients with MET -dysregulated NSCLC. MET ex14 skipping mutations and/or MET amplification usually occur without other oncogenic driver mutations.
CLINICAL LUNG CANCER
(2023)
Article
Oncology
Paul K. Paik, Ravi K. Goyal, Beilei Cai, Mark A. Price, Keith L. Davis, Valerie Derrien Ansquer, Nydia Caro, Teddy R. Saliba
Summary: This study aimed to assess the real-world clinical outcomes of MET exon 14 skipping mutation NSCLC patients with brain metastases who received capmatinib in routine US clinical practice. The results showed substantial effectiveness of capmatinib in both systemic and intracranial treatment, especially in first-line therapy and radiation-naive patients. These findings demonstrate the potential of capmatinib as a promising treatment option for this subgroup of patients.
Article
Oncology
Ravi K. Goyal, Jingchuan Zhang, Keith L. Davis, Martina Sluga-O'Callaghan, Peter A. Kaufman
Summary: This study assessed the treatment patterns and clinical outcomes of using Eribulin in patients with metastatic breast cancer who had previously received IO or ADC treatment. The results demonstrated that Eribulin showed good clinical effectiveness in patients with metastatic breast cancer.
BREAST CANCER-TARGETS AND THERAPY
(2023)
Article
Oncology
Amit G. Singal, Saurabh P. Nagar, Abby Hitchens, Keith L. Davis, Shrividya Iyer
Summary: This retrospective study suggests the clinical effectiveness of lenvatinib monotherapy in a real-world setting among previously treated patients with uHCC, including those previously treated with immunotherapy.
Article
Hematology
Gilles Salles, Stephen J. Schuster, Luca Fischer, John Kuruvilla, Piers Em Patten, Bastian von Tresckow, Sonali M. Smith, Ana Isabel Jiminez Ubieto, Keith L. Davis, Saurabh P. Nagar, Jie Zhang, Vamsi Bollu, Etienne Jousseaume, Roberto Ramos, Yucai Wang, Brian K. Link
Summary: This study aimed to construct a historical control cohort for relapsed/refractory follicular lymphoma (r/r FL) in order to enhance single-arm trials. The findings demonstrate the clinical characteristics and treatment outcomes of r/r FL patients, as well as the treatment limitations and unmet needs for certain patients. By comparing with previous studies, this research provides valuable control data for comparative studies.